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The purpose of this study was to investigate the relationship between bronchoalveolar lavage (BAL)-derived 
parameters of interstitial lung disease and clinical and lung function parameters in 34 patients with sarcoidosis 
and 23 patients with idiopathic pulmonary fibrosis (IPF). BAL findings of healthy individuals served as 
controls. 
Cell content and differentiation of BAL fluid were determined. Oxygen radical (0, ~ ) production of BAL 
cells and of blood polymorphonuclear (PMN) cells was measured. Phenotypes of lung and blood lymphocytes 
were determined by immunoperoxidase staining. In addition, lung function was assessed, chest X-rays were 
made and serum ACE was measured. 
Lymphocyte alveolitis in sarcoidosis was associated with increased alveolar macrophage (AM) O,- 
production (PcO.025 vs. sarcoidosis with normal lymphocyte counts). Patients with extrapulmonary sarcoi- 
dosis had higher CD4KDS ratios in BAL (PcO.025) and shorter disease duration (PcO.01) than those with 
strictly pulmonary sarcoidosis. Disease duration in sarcoidosis correlated inversely with the number of BAL 
cells (r= - 0.38, P<O.O5), the relative and absolute number of lymphocytes in BAL fluid (r= - 0.34, PcO.05 
and r= - 0.44, P<O.Ol, respectively) and the percentage of CD4-positive cells and the CD4/CDS ratio 
(r= - 0.43, PcO.05 and r= - 0.48, PcO.025, respectively). Although significant increases in 0, ~ production 
by BAL cells were observed in both IPF and sarcoidosis, only in sarcoidosis was a higher AM 0, - 
production associated with a significantly lower total lung capacity (r= - 0.67, P<O.O05) and pulmonary 
diffusing capacity 7KO (r= - 0.50, PcO.05). 
In conclusion, our findings show that lung lymphocyte phenotypes differ among patients with pulmonary 
and extrapulmonary sarcoidosis and that 0, - production is upregulated in active sarcoidosis. In addition, 
our findings suggest that different relationships between BAL data and lung function in patients with 
sarcoidosis and IPF may be explained by differences in disease duration. In IPF, disease duration is likely to 
be underestimated because of its insidious onset. In sarcoidosis, the presence of extrapulmonary symptoms, 
helpful to establish an early diagnosis, is associated with significant BAL lymphocytosis. 
Introduction 
Sarcoidosis and idiopathic pulmonary fibrosis 
(IPF) are two disease entities belonging to the group 
of illnesses called interstitial lung diseases (ILD), 
which are characterized by distortion of lung paren- 
chyma architecture. Two major problems present 
themselves in the clinical evaluation and management 
of these diseases. First, lung tissue, i.e. lung biopsy, 
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is often required to establish a correct diagnosis. 
Secondly, an assessment of disease activity is neces- 
sary for treatment follow-up. 
Bronchoalveolar lavage (BAL) provides a reliable, 
easy and safe way to assess inflammatory changes in 
the lungs (l-3) and has been used to identify cellular 
and soluble parameters of disease activity in patients 
with ILD. Increased numbers of polymorphonuclear 
cells (PMN), i.e. neutrophils and eosinophils, as well 
as lymphocytes and alveolar macrophages (AM) may 
be present in BAL fluid of patients with ILD (1,2,4). 
These alveolar inflammatory changes have been des- 
ignated as ‘alveolitis’. Depending on the dominant 
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cell type, lymphocyte alveolitis, as usually found in 
sarcoidosis, and neutrophil alveolitis, as commonly 
found in IPF, can be distinguished. Soluble param- 
eters of disease activity and cell activation include 
reactive oxygen metabolites, e.g. O,- (5-7) and 
lymphokines. In patients with ILD, increased O,- 
production has been demonstrated ($8) and impli- 
cated in the pathogenesis of ILD. Lymphocytes may 
play an important role, both by regulating the release 
of o,- by AM and through the release of several 
lymphokines (9-12). In addition, studies have shown 
that in sarcoidosis, the ratio of CDCpositive or 
inducer lymphocytes to CD8-positive or cytotoxic 
lymphocytes (CD4/CD8 ratio) in the lung is generally 
increased (13-15) whereas in IPF this ratio is more 
likely to be decreased (13). 
In the present study we investigated the relation- 
ship between the afore-mentioned BAL-parameters 
and conventional measures of extent and activity of 
disease, including clinical symptoms, pulmonary 
function, chest X-ray and serum angiotensin convert- 
ing enzyme. Patients with sarcoidosis and patients 
with IPF were studied with respect to these par- 
ameters. The results of both patient groups were 
compared with each other. 
Methods 
STUDY SUBJECTS 
Twenty-three patients with idiopathic pulmonary 
fibrosis (IPF) and 34 patients with newly diagnosed 
biopsy-proven sarcoidosis were included in the study. 
From our laboratory database data from 24 healthy 
individuals were available for comparison. 
BRONCHOALVEOLAR LAVAGE 
Bronchoalveolar lavage (BAL) was performed 
with a flexible bronchoscope after local anaesthesia 
of the airways with lidocaine spray. After rinsing the 
suction canal with 0.3% gelatin solution, the tip of a 
flexible bronchoscope (Olympus B l-IT20, Olympus 
Optical Co., Tokyo, Japan) was wedged in the lateral 
segment of the right middle lobe. Subsequently, ten 
aliquots of 20 ml of phosphate buffered saline of 
37°C were instilled and recovered by gentle vacuum 
suction after each aliquot. 
ISOLATION OF POLYMORPHONUCLEAR CELLS FROM 
BLOOD 
Fifty millilitres of heparinized venous blood was 
diluted 1:l with saline solution for isolation of PMN 
as described previously (16). In short, the red cell 
pellet obtained after Ficoll-Paque separation was 
processed by Dextran sedimentation. The mono- 
nuclear cell fraction was removed and processed 
separately for isolation of lymphocytes (see below). 
The dextran plasma layer containing PMN and 
some erythrocytes was collected and centrifuged. 
The cell pellet was resuspended in PBS and was 
gently layered on a Percoll solution and centrifuged 
for 20 min, after which the PMN layer was removed 
and diluted with PBS to be centrifuged and sub- 
sequently washed with PBS and finally resuspended 
in Hank’s Balanced Salt Solution (HBSS+O.l% 
glucose). The volume and cell content of the 
suspension was determined and served to prepare 
cytocentrifuge preparations. 
ISOLATION OF LYMPHOCYTES FROM BLOOD 
The mononuclear cell fraction obtained after 
Ficoll-Paque separation of peripheral blood was 
washed twice during 10 min at 4°C at 550 g and 250 g 
(1800 and 1200 rpm, respectively) and resuspended in 
HBSS with a maximum volume of 4 ml. The number 
of cells in the suspension was determined in a Coulter 
counter. Cytospin preparations were made, fixed 
with acetone and stored at - 80°C for subsequent 
immunological analysis. 
WORK-UP BAL CELLS 
The lavage fluid was filtered through a venous 
infusion filter (Curapharm@, Medica B.V. Hospital 
Supplies, The Netherlands) to remove mucus and 
centrifuged at 550 g (1800 rpm) at 4°C for 10 min. 
The unconcentrated supernatant was stored at 
- 80°C for subsequent analysis. The cell pellet was 
resuspended and washed twice with centrifugation at 
4°C for 10 min at 675 g (2000 rpm) and 330g 
(1400 rpm), respectively. Cytospin preparations were 
made from 1OO;ul aliquots of the lavage cell suspen- 
sion (0.3 x lo6 cells ml- ‘) on BSA-coated slides. 
Two preparations from each patient were stained 
with May-GriinwaWGiemsa. Cell differential counts 
of 500 cells were performed on two slides and the 
average count of both slides was taken as the definite 
cell differential. Additional acetone fixed cyto- 
spins were stored at - 80°C for future lymphocyte 
staining. 
OXYGEN RADICAL PRODUCTION 
Oxygen radical production of BAL cells and blood 
PMN was measured as the superoxide dismutase 
(SOD) inhibitable reduction of cytochrome c as 
described previously (16). In short, a volume of cell 
suspension containing 4 x 10’ cells was incubated 
with a mixture containing cytochrome c with or 
without SOD and Phorbol Myristate Acetate 
(PMA, Sigma) as a soluble stimulus at concen- 
trations of 5, 10 and 20 ng ml- ‘. The incubation 
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mixture, at a final volume of 0.5 ml, was collected 
in polystyrene tubes. Tubes without PMA were 
included to measure spontaneous reduction, and the 
total reduction was checked by including tubes with 
0.085 ml of a saturated sodium hydrosulfite solution 
(Sigma). The reaction mixuters were prepared at 
room temperature and placed in a water bath at 
37°C for 10 min. After termination of the reaction 
by centrifugation the optical density at 550 nm 
wave length was determined in a spectrophotom- 
eter. The oxygen radical production was expressed 
as nmol cytochrome c reduction per 15 min per 
400 000 cells. 
For the BAL cells, oxygen radical production was 
corrected for the percentage of lymphocytes, since 
lymphocytes are not capable of producing 0, -. 
Consequently, 0, - production was expressed as 
nmol cytochrome c reduction per 15 min per 400 000 
O,- producing cells, i.e. AM, eosinophils and neu- 
trophils (17). In healthy controls and patients with 
sarcoidosis, who all had less than 10% of eosinophils 
and neutrophils, the proportion of these cells in the 
total O,- production was considered neglectable 
and O,- production was again adjusted to be 
expressed as nmol cytochrome c reduction per 15 min 
per 400 000 AM. 
LYMPHOCYTE SUBSET STAINING 
Lymphocyte phenotypes of cytospin preparations 
of BAL cells and blood lymphocytes were deter- 
mined by the immune peroxidase method using 
monoclonal antibodies against CD3, CD4, CD8, 
CD22 and HLA-Dr (Becton Dickinson). Cytospin 
preparations were washed in PBS of pH 7.2 for 
5 min before and after a 45 min incubation with the 
respective monoclonal antibodies. Subsequently the 
cytospins were incubated with peroxidase-labelled 
rabbit anti-mouse-Ig serum (Dako Copenhagen) for 
45 min followed by another washing in PBS for 
5 min. The substrate for the enzymatic reaction, 
3-amino, 9-ethylcarbazol was added. After 10min 
the preparations were washed with a citrate buffer 
and rinsed with distilled water. Preparations were 
stained with Mayer’s haematoxilin, rinsed briefly in 
water and mounted in Kaiser’s glycerin-gelatin. At 
least 300 lymphocytes were counted and the num- 
bers of cells positive for the respective antibodies 
were expressed as a percentage of the total number 
of lymphocytes. 
LUNG FUNCTION 
Lung volumes were measured by helium dilution 
according to standardized techniques. Predicted 
values according to the EGKS (18) were applied. 
Other spirometric parameters such as slow inspira- 
tory vital capacity (IVC), forced expiratory volume 
in one second (FEV,), inspiratory volume in one 
second (FIV,) were measured with a standard 
water-sealed spirometer. FEVJIVC and FIV,/IVC 
ratios were calculated to correct for restriction. 
Values of IVC, FEV,, FIV, and total lung capacity 
(TLC) were expressed in litres BTPS (body tem- 
perature, pressure, saturated). The transfer factor 
for carbon monoxide (Z”rC0) was determined using 
the single breath technique of Krogh, as modified 
by Ogilvie (19) and Cotes (20). The components of 
7tC0, the diffusing capacity of the alveolocapillary 
membrane (D,), and the pulmonary capillary blood 
volume (I’,), were determined from triplicate 
measurements of Z’LCO at high (88%) and low 
(19.2%) inspiratory oxygen concentrations. The 
7tCO values, breathing air, were corrected for 
haemoglobin concentrations according to Cotes 
(20) to obtain Z’LCO values under standard con- 
ditions. D, and k’, were calculated following the 
equation originally devised by Roughton and 
Forster (21). fiC0 and D, were expressed in 
mmolkPaa’min-i, V, was expressed in ml. Pre- 
dicted values were taken from Cotes (20). All pul- 
monary function tests were performed at room 
temperature, with the patient in a steady state 
condition. Pulmonary function parameters were 
considered abnormal when below 80% of the 
predicted value. 
ADDITIONAL STUDIES 
Chest X-rays were performed according to routine 
procedures, judged for the presence of interstitial 
changes, and graded accordingly to well accepted 
criteria. 
Determination of serum angiotensin converting 
enzyme (ACE) was performed as part of the patient 
characterization. 
DATA ANALYSIS 
Data were analysed with the SPSS/PC+statistical 
package, version 3.0. For between group compari- 
sons Student’s t-test or the Mann-Whitney ranked 
sum test were used. For comparison of multiple 
groups one-way analysis of variance followed by 
Duncan’s multiple range test was used. Correlations 
were computed with Spearman’s ranked correlation 
test. Logarithmic transformations were used when 
necessary to normalize distributions of test variables. 
The null hypothesis was rejected when it had a 
probability (P value) of 5% or less. Individual P 
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Table I Demographic and BAL characteristics of the subjects (mean f SEM) 
Healthy IPF Sarcoidosis 
Number 
Age 
Sex (male/female) 
Smokers 
Disease duration (years) 
Treated 
Recovery 
Cells ml ’ 
Alv. mat. 
Neutrophils 
Eosinophils 
Lymphocytes 
T-cells 
CD4+ cells 
CD8+ cells 
CD4+/CD8 + ratio 
B-cells 
HLA-Dr + 
(“A) 
( x 103) 
(“!I 
j;)103 ml-‘) 
1,,103 ml- i) 
ii)lO’ ml- i) 
(G 103mll’) 
WJ) 
~“/x)lO’ ml ‘) 
r$,103 ml-‘) 
(i 10’mll’) 
WI 
i”;)lO’ ml- ‘) 
(i 103ml-i) 
24 
41.7 3~ 2.7 
1717 
6 
72.2 f 2.9 64.9 f 3.0 63.6 zk 2.8 
163.5 f 35.1 321.2 f 56.8** 221.6 f 25.4** 
89.7 f 1.2 61.5 f 6.4** 72.4 f 3.2*** 
1496 f 336 196.3 f 48.6 156.6 f 20.0 
1.3*0.3 13.9 f 4.5*** 1.8 f 0.3ttt 
2.29 f 0.76 54.8 f 34.6*** 4.18 f 1.19ttt 
0.29 f 0.13 7.8 + 2,7*** 0.73 f 0.17*tt 
0.72 f 0.47 13.6 f 4,2*** 1.77 f 0.51*tt 
8.6 f 1 .O 16.4 f 4.1 25.1 f 3.3***t 
10.8 f 1.7 55.9 f 18.2* 59.0+ 11.0*** 
n=S n=8 n=25 
71.5 zk 2.05 91.8 f 1.91** 89.1 f 1.67*** 
5.25 f 1.16 70.0 f 23,7** 58.9 f 1 l-O*** 
45.0 f 2.3 34.9 f 9.4t 56.7 i 3.4* 
3.29 f 0.73 24.9 f 9.7* 40.6 i 8.6*** 
32.3 f 1.7 49.8 f 9.3t 24.0 f 2.7* 
2.35 f 0.53 40.8 z!z 16.6** 15.2 f 244** 
1.40 f 0.02 2.81 f 2.lt 4.13 f 1.0 
11.3*0.7 2.38 f 0.50** 1.60 f 0.28*** 
0.84 f 0.19 2.03 f 0.85 1.20 f 0.38 
1.25 f 0.37 24.4 f 8.9** 13.5 f 3.1*** 
0.063 f 0.021 24.0 f 16.2** 7.14 f 1.42*** 
23 34 
58.2 f 2.9** 35.1 f 1.7tt 
12/11 23/l 1 
5 6 
2.04 f 0.66 1.59 f 0.51 
Differences with healthy controls: *: PcO.05; **: P<O.O05; ***: P<O.O005. 
Differences between IPF and sarcoidosis: t: P<O.O5; tt: P<O.O05; ttt: P<O.O005. 
values are indicated in parentheses in text and by 
symbols in figures. 
Results 
SUBJECT CHARACTERISTICS 
Table 1 presents the clinical and BAL data of the 
subject groups. Patients receiving treatment, either 
corticosteroids or immunosuppressive drugs, were 
not significantly different from untreated patients 
with respect to BAL parameters, lung function and 
lymphocyte subsets. Therefore, they were all included 
in all analyses. 
Demographic characteristics 
Patients with IPF were significantly older than 
the other two groups (WO.005 in both analyses). 
There were significantly more patients with a 
known duration of complaints and/or symptoms of 
less than 3 months in the group of patients with 
sarcoidosis than in the group of patients with IPF 
(PCO.05). 
BAL cell difSerentiation 
The total cell count per ml BAL fluid was 
increased in both patient groups as compared to 
normals. Because of these differences the absolute 
numbers of the various cell types are included in the 
table. Based on the BAL cell differentiation in our 
healthy controls, BAL cell differentiations in 
patients were considered to be normal when the 
lymphocyte percentage was 5 17 and the combined 
neutrophil and eosinophil count was < 10%. 
According to these criteria, 14 sarcoidosis patients 
and nine IPF patients had a normal BAL cell 
differentiation. All 20 remaining patients with sar- 
coidosis had lymphocyte alveolitis without increased 
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Fig. I 0, - production by BAL cells in all subject groups, distinguished by BAL cell profile. 0, - on y-axis expressed as 
nmol cytochrome c reduction per 15 min by 400 000 BAL cells. (a) Unstimulated 0, - production; (V) 0, - production 
with PMA 5 ng ml - ‘; (0) 0, production with PMA 10 ng ml - ‘; (0) O,- production with PMA 20 ng ml - ‘. BAL abn: 
abnormal BAL cell differentiation (see text for criteria). 
PMN percentages. In the 14 IPF patients with 
abnormal cell differentiations simultaneous increases 
in the percentage of lymphocytes and PMN were 
observed. 
BAL lymphocyte phenotypes 
Due to an insufficient number of cells recovered 
or a small percentage of lymphocytes, BAL lym- 
phocyte phenotypes could not be determined in 16 
controls and 24 patients. BAL lymphocytes were 
analysed in eight non-smoking controls. In the 
patient groups the ranges of the lymphocyte subsets 
were broader than in the healthy controls. BAL 
lymphocyte phenotypes showed characteristic 
changes for IPF and sarcoidosis (Table 1). In both 
diseases the proportion of activated lymphocytes, as 
measured by expression of HLA-Dr, was increased 
as compared to normals. 
Sarcoidosis patients with lymphocyte alveolitis had 
a significantly increased percentage of CD4-positive 
cells (57.3 f 4.1 vs. 450 f 2.3, P<O.Ol), a decreased 
percentage of CD%positive cells (20.9 * 2.4 vs. 
32.3 * 1.7, P<O.Ol) and a higher CD4KD8 ratio 
(3.68 f 0.61 vs. 1.40 & 0.02, PcO.01) in BAL than 
healthy controls. Sarcoidosis patients with normal 
BAL cell differentiation did not differ significantly 
from controls. 
BAL oxygen radical production 
Data from six controls, 14 IPF patients (five with 
normal BAL cell differentiation and nine with abnor- 
mal differentiation, data not shown) and 22 sarcoido- 
sis patients (eight with normal BAL differentiation 
and 14 with lymphocyte alveolitis) were obtained. In 
addition to these data, ten healthy controls were 
included in whom only BAL cell differentiation and 
BAL O,- production were determined (see Fig. 1). 
When the BAL cell differentiation was normal, 0, ~ 
production was similar in patients and healthy con- 
trols. As a whole, the group of patients with IPF 
produced significantly more 0, ~ after stimulation 
with PMA than the other groups; PMA 5 ng ml- ‘: 
PcO.05 vs. sarcoidosis; PMA 10 and 20 ng ml- ‘: 
P<O.O25 vs. controls, P<O.O05 vs. sarcoidosis, 
presumably as a result of the high proportions of 
neutrophils and eosinophils in these patients. How- 
ever, no differences in 0, - production were found 
between IPF patients with normal and abnormal 
BAL cell profiles. 
Expressed per 400 000 AM, patients with sarcoid 
lymphocyte alveolitis produced significantly more 
O,- after stimulation with PMA, than sarcoidosis 
patients with normal BAL cell profiles (see Fig. 2). 
These results remained the same when only non- 
smokers were analysed. 
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Fig. 2 O,- production by alveolar macrophages (AM) in healthy controls and patients with sarcoidosis, distinguished by 
BAL cell profile. 0, on y-axis expressed as nmol cyotchrome c reduction per 15 min by 400 000 AM (corrected for % of 
lymphocytes and polymorphonuclear cells). (a) Unstimulated O,- production; (V) O,- production with PMA 
5 ng ml ‘; (0) 0, - production with PMA 10 ng ml - ‘; (0) O2 production with PMA 20 ng ml I. BAL abn: abnormal 
BAL cell differentiation (see text for criteria). 
SYSTEMIC DISEASE MANIFESTATIONS 
Blood lymphocyte phenotypes 
Blood lymphocytes were analysed in eight non- 
smoking controls, 11 IPF patients and 23 sarcoidosis 
patients (data not shown). The percentage of 
T-lymphocytes was increased in both patient groups 
as compared to the healthy controls. This could not 
be attributed to an increase in one particular pheno- 
type. Rather, a decreased percentage of CD8-positive 
cells in patients with sarcoidosis was observed 
(WO.05). Percentages of B-cells, CDCpositive cells 
and CD4KD8 ratios were similar in both patient 
groups and controls. 
Blood PMN oxygen radical production 
Oxygen radical (0, -) production of blood PMN 
was measured in nine healthy controls, 14 IPF and 26 
sarcoidosis patients (data not shown). The O2 - 
production of healthy controls was not significantly 
different from that of patients with IPF. Patients with 
sarcoidosis had higher spontaneous and stimulated 
O,- production rates in blood than the healthy 
controls, being significant for PMA 10 ng ml-’ 
(basal: 1.30 & 0.25 vs. 0.97 f 0.21, PzO.08; PMA 
5 ng ml- ‘: 12.39 & 1.50 vs. 7.82 f 0.90, PzO.12; 
PMA 10 ng mll ‘: 18.19 f 1.59 vs. 10.54 & 1.02, 
PCO.05). 
RELATIONSHIPS BETWEEN BAL AND OTHER PARAMETERS 
OF DISEASE 
Disease duration 
Disease duration in patients with sarcoidosis 
showed a significant inverse correlation with the 
number of BAL cells per ml of BAL fluid (r= - 0.38, 
P<O.O5), the percentage and absolute number of 
lymphocytes in BAL (r= - 0.34, PcO.05 and 
r= - 044, PcO.01, respectively), as well as the num- 
ber of CD4-positive cells in BAL (r= - 0.43, PcO.05) 
and the CD4KD8 ratio (r= - 0.48, PcO.025). In 
IPF, disease duration did not correlate with BAL 
parameters. 
Lung function 
Patients with IPF had significantly lower lung 
volumes and diffusing capacity than patients with 
sarcoidosis (data not shown). In the latter group, 
pulmonary function, especially TLC, was directly 
related to BAL numbers of T-lymphocytes per ml 
(rz0.54, P<O.O25), CD4-positive cells per ml 
(r=O.57, PcO.01) and B-cells per ml (rx0.67, 
P<O.O05). By contrast, TLC was inversely correlated 
with O,- production, both PMA-stimulated 
[r= - 0.67 (P<O.O02) with 20 ngml-’ PMA] and 
unstimulated (r= - 0.46, P=O.O5). Similar relation- 
ships with stimulated O,- production were seen for 
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-(a) 0 A IPF, n = 12, r = -0.34,0.05 < P < 0.10 
q Sarcoidosis, n = 19, r =-0.67, P < 0.002 
140 
6) _ 
I 
. IPF, 10, n = r = -0.26, 0.05 < P < 0.10 
120- ,o q Sarcoidosis, n = 20, r = -0.50, P < 0.05 
0 6 12 18 24 30 
0; Production BAL with 20 ng ml-’ PMA 
Fig. 3 Relationship between BAL O2 production and TLC (a) and 7X0 (b) in patients with sarcoidosis and IPF. 0, - 
expressed as nmol cytochrome c reduction in 15 min; solid regression lines: IPF; dashed regression lines: sarcoidosis. 
7WO: r= - 0.50 (WO.05) with 20 ng ml- ’ PMA 
(Fig. 3). In patients with IPF, on the other hand, no 
clearly significant relationships could be found, 
although IVC, TLC and 7WO tended to correlate 
with PMA-stimulated 0, - (0.05<P<O.10). 
Clinical symptoms 
Patients with extra-pulmonary sarcoidosis had a 
shorter disease duration (WO.01) than those with 
strictly pulmonary disease. Furthermore, patients 
with extra-pulmonary manifestations also had a 
higher percentage of CD4-positive cells (P<O.O5), a 
lower percentage of CD&positive cells (WO.025) and 
accordingly a higher CD4/CD8 ratio (PdO.025, Fig. 
4). There were no differences in pulmonary function, 
blood lymphocyte phenotype or 0, - production. 
Chest roentgenogram 
Chest X-rays of eight patients with sarcoidosis 
showed stage I abnormalities, seven had stage II and 
17 had stage III. Lymphocyte alveolitis was associ- 
ated with stage I and III, as opposed to normal BAL 
in patients with stage II X-rays. No differences in 
pulmonary function, O,- production by BAL cells 
or disease duration were observed. All IPF patients 
had interstitial abnormalities on their chest X-ray. 
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Fig. 4 Lymphocyte phenotypes in BAL of healthy controls and patients with sarcoidosis. Lymphocyte phenotypes 
expressed as percentages of the total number of lymphocytes. (a) CD4-positive cells; (7) CDI-positive cells; (0) CD4 to 
CD8 ratio (plotted against right y-axis); pulmonary: sarcoidosis restricted to the lungs; extra-pulm: pulmonary sarcoidosis 
with extra-pulmonary manifestations. 
Angiotensin converting enzyme 
Serum ACE levels in our sarcoidosis patients 
ranged from 5-89Uml-’ (normal values 
~45 U ml- ‘). We found a positive correlation 
between serum ACE levels and PMA-stimulated 
0, - production by BAL cells (PMA 10: r=0.54, 
PMA 20: r=0.50, PcO.025 in both analyses). 
Discussion 
In the present study we investigated the relation- 
ship between clinical, roentgenological, lung func- 
tional and BAL-derived parameters of interstitial 
lung disease in patients with sarcoidosis and idio- 
pathic pulmonary fibrosis (IPF) in order to reveal 
clues pointing to different pathogenetic mechanisms 
in these diseases. Indeed, we found that correlations 
between BAL and conventional clinical parameters 
were more notable in our patients with sarcoidosis 
than in those with IPF and suggest that this may 
reflect the fact that the latter group had more long- 
standing disease than the patients with sarcoidosis. In 
both diseases, lung lymphocytes showed increased 
expression of HLA-Dr, indicative of increased lym- 
phocyte activation. Short disease duration in sarcoi- 
dosis was associated with more severe abnormalities 
of BAL parameters and with the presence of extra- 
pulmonary symptoms. Sarcoid lymphocyte alveolitis 
was associated with increased activation of alveolar 
macrophages as assessed by oxygen radical (OJ 
production. In sarcoidosis high BAL 0, - production 
was associated with more severe impairment of lung 
function, especially of TLC and 7X0. We also 
found that high serum ACE levels were associated 
with increased 0, - production by BAL cells. In 
IPF, although O,- production by BAL cells was 
higher than in sarcoidosis and controls, there was no 
significant correlation with lung function. 
Our data concerning cell composition and lympho- 
cyte phenotypes in BAL fluid compare well with data 
found by others (l-3,13-15). Lymphocyte alveolitis is 
a common finding in sarcoidosis, whereas neutrophils 
and eosinophils usually dominate the alveolitis in 
IPF. The predominance of CD4 positive helper/ 
inducer T-cells in sarcoidosis and of CD8 positive 
suppressorkytotoxic T-cells in IPF is also well estab- 
lished. In addition, our measurements of HLA-Dr 
expression revealed that significant proportions of 
the lung lymphocytes were activated, in IPF as 
well as in sarcoidosis, but we did not distinguish be- 
tween CD4 and CD8 positive cells in this respect. 
Intriguingly, the mechanisms of these differences 
remain unclear and our data do not allow us to 
elaborate on them. 
In the case of sarcoidosis at least, disease duration 
is a critical factor in the analysis of BAL data. Ward 
et al. (22) found higher lymphocyte numbers and 
CD4KD8 ratios in BAL in patients with shorter 
disease duration. Our findings confirm these relation- 
ships. In addition, we found that patients with 
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extrapulmonary symptoms, such as erythema nodo- 
sum and uveitis had more severe disruptions of lung 
lymphocyte phenotypes than patients with sarcoid- 
osis restricted to the lungs. The presence of extra- 
pulmonary symptoms was also associated with short 
diseases duration, which probably explains the 
relationships with lung lymphocyte phenotypes. 
The presence of extrapulmonary manifestations 
was not reflected by, abnormalities of the lymphocyte 
phenotypes in blood. Apparently, the organs affected 
act immunologically independent. 
Oxygen radicals, i.e. highly reactive oxygen 
metabolites produced by AM and PMN, have been 
incriminated in the pathogenesis of ILD by several 
authors (6,7,23,24) especially in IPF. Consistent with 
this, we have also found elevated 0, ~ production 
by BAL cells in the patients with IPF in this study. 
In sarcoidosis, AM are the most important sources 
of 0, - (5,25), and an upregulatory effect of 
T-lymphocytes has been proposed (8). Indeed, we 
found relationships between oxygen radical produc- 
tion, lymphocyte alveolitis and lung function com- 
patible with this hypothesis, but only in sarcoidosis. 
The relationship between oxygen radical production 
and lung function impairment, however, largely 
depends on the temporal relationship between the 
release of 0, and the occurrence of lung function 
disturbances. Lung function reflects the cumulative 
effect of lung damage in the past and present, 
whereas 0, - production is a parameter of current 
cell activation. Therefore, the relationships between 
these parameters should be assessed at an early stage 
in the disease, when previous episodes of increased 
0, - release do not mask the relationships. Thus, 
disease duration is a critically important factor in the 
interpretation of these results. Unfortunately, IPF 
has an insidious onset and the absence of early 
clinical signs, such as erythema nodosum in sarcoi- 
dosis, usually prevents an early diagnosis. This may 
explain why we did not find a relationship between 
BAL 0, - production and lung function or between 
lymphocyte phenotypes and disease duration in IPF. 
The correlation of serum ACE levels with BAL 0, - 
production in sarcoidosis may be seen as the simul- 
taneous reaction of two markers of cellular activity. 
In addition, we found that BAL lymphocytes in 
sarcoidosis was associated with increased O,- 
production by BAL cells, suggesting that in active 
sarcoidosis lymphocytes may upregulate 0, - 
production by AM. 
These considerations imply that activation par- 
ameters in these diseases have to be interpreted 
with caution in clinical practice. Further studies of 
patients in a comparable stage of the disease and 
follow-up investigations will be necessary to define 
the significance of abnormalities at a given point in 
the course of the disease. 
In conclusion, our findings show that lung lympho- 
cyte phenotypes differ among patients with pul- 
monary and extrapulmonary sarcoidosis and that 
0, - production by BAL cells is upregulated in active 
pulmonary sarcoidosis. In addition, our findings 
stress the importance of disease duration in the 
analysis of BAL data and their relationship to the 
clinical disease state in sarcoidosis. In IPF, given its 
insidious onset, relationships between BAL param- 
eters and lung function are difficult to interpret 
because disease duration is difficult to assess. 
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